Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 4, 484-494, April 2007; doi:10.1634/theoncologist.12-4-484
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ozer, H.
Right arrow Articles by Dreiling, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ozer, H.
Right arrow Articles by Dreiling, L.

Symptom Management and Supportive Care

Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use

Howard Ozera, Barry Mirtschingb, Michael Raderc, Susan Luedked, Stephen J. Nogae, Beiying Dingf, Lyndah Dreilingf

aSection of Hematology/Oncology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA; bCenter for Oncology Research and Treatment, PA, Dallas, Texas, USA; cUnion State Bank Cancer Center, Nyack Hospital, Nyack, New York, USA; dSt. Louis Cancer & Breast Institute, St. Louis, Missouri, USA; eAlvin & Lois Lapidus Cancer Institute, Baltimore, Maryland, USA; fAmgen Inc., Thousand Oaks, California, USA

Key Words. Pegfilgrastim • Chemotherapy • Febrile neutropenia • Cancer • Community medicine • Medical oncology

Correspondence: Howard Ozer, M.D., Ph.D., Section of Hematology-Oncology, University of Oklahoma Health Science Center, PO Box 26901, Williams Pavilion, Room WP2080, Oklahoma City, Oklahoma 73190, USA. Telephone: 405-271-4022; Fax: 405-271-3020; e-mail: howard-ozer{at}ouhsc.edu

The impact of first- and subsequent-cycle growth factor use in the community setting has not been studied extensively. We conducted this large, prospective, noncomparative study to assess neutropenia and related complications in patients receiving myelotoxic chemotherapy with pegfilgrastim support in community practices. Patients ≥18 years old with cancers other than leukemia or myelodysplastic syndrome, including those with major comorbidities, were eligible. Pegfilgrastim (6 mg) was to be administered ~24 hours after chemotherapy in all cycles (minimum, four cycles). A total of 2,112 patients was included in the analyses. The most common tumor types were breast cancer (46%), non-Hodgkin's lymphoma (15%), and non-small cell lung cancer (13%). Chemotherapies administered most often were a platinum plus a taxane (18%), and anthracycline plus an alkylating agent (18%), and a taxane plus an anthracycline plus an alkylating agent (16%). The percentage of patients with neutropenia-related hospitalization was 2.9% in cycle 1 and 5.6% across all cycles. Chemotherapy dose reductions and delays were attributed to neutropenia in 1.8% and 0.9% of patients, respectively, in cycle 2 and 2.9% and 2.1% of patients, respectively, across all cycles. Febrile neutropenia (absolute neutrophil count <1.0 x 109/l with temperature ≥38.2°C) occurred in 3.6% of patients in cycle 1 and in 6.3% of patients across all cycles. The most frequently reported serious adverse events were febrile neutropenia (3.4%), neutropenia (2.6%), and dehydration (2.6%). Bone pain (0.1%) was the only related serious adverse event reported in more than one patient. Data from this community-based study suggest that patients undergoing chemotherapy benefit from pegfilgrastim support beginning in the first cycle of chemotherapy.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
The OncologistHome page
T. J. Smith and J. L. Khatcheressian
Re: Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
Oncologist, December 1, 2007; 12(12): 1464 - 1464.
[Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement